| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |